Pediatric Risk Factors for Severe Respiratory Infections
Underlying chronic conditions and hospital transfers are major indicators of severe disease in pediatric patients with respiratory tract infections.
Tag: RSV respiratory syncytial virus
All
Latest
Pediatric Risk Factors for Severe Respiratory Infections
Underlying chronic conditions and hospital transfers are major indicators of severe disease in pediatric patients with respiratory tract infections.
Read More
Maternal RSV Vaccine Cuts Infant Hospitalizations Nearly 70%
Real-world data published in JAMA Network Open confirm the effectiveness of the RSVpreF vaccine in protecting newborns from respiratory syncytial virus.
Read More
Lawsuit Alleges 1960s Infants Given RSV Vaccine Without Consent
The families of two infants who died in the 1960s are suing the federal government alleging the babies received an experimental RSV vaccine without the knowledge or consent of their families, according to a report by The New York Times.
Read More
Maternal RSV Vaccination Cut Infant Hospitalization Risk by 80%
Maternal RSV vaccination reduced infants’ hospitalization risk by more than 80% when administered at least 14 days before birth.
Read More
Enanta Pharma to Present Data for RSV, STAT6 Therapies at ATS 2026
Enanta Pharmaceuticals will present data on its RSV therapy zelicapavir and on EPS-3903, an oral STAT6 inhibitor, at ATS 2026.
Read More
Shared Bathroom Vents Linked to COVID-19 Aerosol Spread
Vertical ventilation ducts in residential buildings can facilitate the spread of infectious respiratory aerosols in multi-family buildings.
Read More
Phase II Trial for Antiviral Nasal Spray Advances to Next Stage
The once-weekly INNA-051 treatment from ENA Respiratory aims to prime the immune system to protect high-risk patients from influenza, RSV, and other respiratory viruses.
Read More
Significant Gaps in Vaccine Uptake, Trust for US Adults
An NFID initiative provided evidence-based guidance on influenza, COVID-19, and RSV during the 2025-2026 season.
Read More
Roche Launches New Respiratory Pathogen Test in CE Markets
The new Roche diagnostic test identifies 25 viruses and bacteria to help clinicians provide...
Read More
RSV Vaccine Arexvy Gets Expanded Approval for At-risk Adults 18-49
The expanded approval means Arexvy is now indicated for all adults aged 60 and older, and adults aged 18–59 at increased risk for LRTD caused by RSV.
Read More
ACP: Adults 75+ Should Get a Protein Subunit RSV Vaccine
The American College of Physicians recommends an RSV vaccine for all adults age 75 and older.
Read More
Infant Immune Response May Explain RSV Severity Compared to SARS-CoV-2
A study found that infant immune systems respond very differently to RSV and SARS-CoV-2, with important treatment implications.
Read More
AAP Issues Immunization Schedule for 2026
The 2026 AAP recommendations remain largely unchanged from 2025 but differ from the CDC’s new immunization schedule.
Read More
Flowflex 4-in-1 RSV, Flu A/B, COVID Home Test Available
The Flowflex Plus 4-in-1 is the first single home test FDA-cleared for adults and children 6 months or older to test for RSV, influenza A/B, and COVID-19.
Read More
New Evidence Reshapes RSV Prevention Strategies
Recent advances in maternal vaccines and long-acting monoclonal antibodies have broadened the scope of RSV prevention, but questions remain.
Read More
CDC/HHS Remove Vaccines from Childhood Immunization Schedule
The CDC and HHS reduced the federally recommended childhood immunization schedule from 17 to 11 vaccinations, removing shots for seasonal flu and other infectious diseases.
Read More
Nirsevimab Greatly Reduced Severe RSV in Infants
For infants in their first RSV season, the monoclonal antibody Nirsevimab (Beyfortus) was 80% effective against RSV-related ICU admission and 83% effective against acute respiratory failure.
Read More
RSV Awareness Month: Preventing Infant Hospitalizations
For RSV awareness month (October), the American Lung Association is spotlighting new data that show a dramatic decrease in RSV-related hospitalizations among infants.
Read More
Reduced RSV Hospitalizations in Infants Treated with Nirsevimab
Researchers examined the effectiveness of nirsevimab during the 2024–2025 RSV season using a large, multi-institutional dataset.
Read More
EU Panel Recommends Approval of Enflonsia for RSV Prevention
The European Medicines Agency’s CHMP recommended Enflonsia to prevent RSV lower respiratory tract disease in neonates and infants during their first RSV season.
Read More
AMDI Submits Fast PCR Test for Clearance
The AMDI Fast PCR Mini Respiratory Panel is a multiplexed RT-PCR test for the simultaneous detection of Flu A, Flu B, RSV, and SARS-CoV-2 in under 10 minutes.
Read More
One Dose of RSV Vaccine Prevented Hospitalizations for Two Seasons
One shot of an RSV vaccine protects adults ages 60 or older from RSV-associated hospitalization and critical illness during two consecutive RSV seasons.
Read More
CDC Predicts Possibility of Higher COVID-19 Hospitalizations for 2025-26 Season
CDC’s annual respiratory disease season outlook predicts similar peak hospitalization rates for COVID-19, influenza and RSV — but a higher hospitalization rate for COVID-19 if a new variant emerges.
Read More
Preventing Flu/RSV-related Lung Damage in Young Children
Researchers want to understand why some babies and toddlers get so much sicker from viral infections of flu and RSV.
Read More